Xinkanghe
Latest round
- Series B
Last raised
- Jul 2023
Total raised
- $30M
Investors
- 12
About Xinkanghe
Established in 2015 and based in Suzhou, China, Xinkanghe is a biotechnology company that engages in drug research and development. The company's CSO, Dong Chen, is the founding dean of Shanghai Institute of Immunotherapy Innovation and a professor of Tsinghua University School of Medicine. Its first antibody drug for the treatment of autoimmune diseases received clinical trial approvals in February 2020. The company focuses on the development of new targets or innovative combinations of drugs for oncology and autoimmune inflammatory diseases, leading the way in the development of innovative immunotherapeutic antibodies.
Who invested in Xinkanghe
12 investors across 3 rounds
See all investors in Xinkanghe
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Xinkanghe
Who invested in Xinkanghe?
Xinkanghe has 12 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Xinkanghe raised?
Xinkanghe has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Xinkanghe last raise money?
Xinkanghe's most recent round on record is a Series B, in Jul 2023.
What does Xinkanghe do?
Established in 2015 and based in Suzhou, China, Xinkanghe is a biotechnology company that engages in drug research and development.
Where is Xinkanghe headquartered?
Xinkanghe is headquartered in Suzhou, China.
Which VCs invest in companies like Xinkanghe?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Xinkanghe's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Xinkanghe? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.